间充质干细胞移植治疗糖尿病的研究进展

糖尿病尤其是1型糖尿病(T1DM),很大程度上与先天免疫缺陷有关,自身免疫攻击导致胰岛β细胞的破坏和胰岛素分泌不足,目前尚无有效方法根治糖尿病。间充质干细胞(mesenchymal stem cells, MSCs)具有强大的增殖分化能力及免疫调节功能。迄今为止,MSCs不论在体外诱导分化产生产胰岛素细胞(IPCs),还是动物试验,均表现出令人鼓舞的效果,但研究仍处于早期阶段。本文介绍MSCs体外衍生为IPCs,作为一种潜在的治疗方法在实验动物模型以及在人体中的应用。
Diabetes mellitus, especially type 1 diabetes mellitus (T1DM), is largely related to an innate defect in the immune system, resulting in the destruction of islet β cells and insulin inadequate secretion due to autoimmune attack. There is no effective method to cure diabetes at present. Mesenchymal stem cells (MSCs) have powerful capabilities of proliferation and differentiation, and offer a promising possibility for novel therapy. MSCs' potential of transdifferentiation into insulin-secreting cells (IPCs) in vitro show us a stimulating inspiration. This review introduce a new approach of MSCs-derived IPCs, as a potential therapeutic benefit for T1DM in experimental animal models as well as in human studies